Halia Therapeutics initiated treatment with HT-6184, a novel NLRP3 inhibitor, in an initial participant for its early-stage Phase 2a study aimed at addressing lower-risk types of myelodysplastic conditions.

Agomab Initiates First-Stage Research Trial on AGMB-447 with Healthy Participants and Individuals Diagnosed with Idiopathic Pulmonary Fibrosis.

FDA has accorded an expedited evaluation to the drug Tarlatamab, developed by Amgen, which is aimed at treating advanced-stage small cell lung cancer.

Maze Therapeutics has commenced the administration phase of its Phase 1 clinical evaluation of MZE829 to test subjects in good health.

1ST Biotherapeutics, Inc. breaks new ground as it initiates the first human trial stage I/II by administering FB849, to individuals with progressive solid cancers

C4 Therapeutics, Inc., a company developing targeted protein degradation drugs, has announced early results from its Phase 1/2 trial's initial dose-escalation stage. The trial evaluates CFT7455, a unique MonoDAC™ agent targeting IKZF1/3 proteins, for treating multiple myeloma and non-Hodgkin lymphomas.

Shattuck Labs Reveals Promising Early Results from Continual Phase 1 A/B Clinical Study of SL-172154 Combined with Azacitidine in Newly Diagnosed Advanced Myelodysplastic Conditions (HR-MDS) and TP53 Mutation-Positive Acute Myeloid Leukemia Patients.

Plexium has begun dosing in a Phase 1 trial for its oral drug PLX-4545, a molecular glue degrader targeting the previously "undruggable" transcription factor IKZF2, also known as Helios.

The European Commission has sanctioned Blueprint Medicines' drug AYVAKYT® (avapritinib) as the exclusive therapeutic option for indolent systemic mastocytosis.

Clover Biopharmaceuticals, Ltd. has announced the enrollment of the first group of participants for its Phase I clinical trial evaluating the SCB-1019 vaccine against Respiratory Syncytial Virus (RSV).

The FDA is reviewing the updated New Drug Application (NDA) for TransCon PTH (also known as Palopegteriparatide) meant for the treatment of hypoparathyroidism in adults.

Vertex Pharmaceuticals Incorporated declared favorable outcomes from its Phase 2 trial assessing various dosages of the targeted NaV1.8 inhibitor, VX-548, in individuals suffering from painful diabetic peripheral neuropathy.